Aripiprazole
Approved · EMAAlso known as Abilify, Opipza, Aripiprazol, Aripiprazolum.
Recent clinical, regulatory, research and industry developments relating to this drug.
Dopamine and Sensorimotor Function in Stuttering
A Phase II Study to Test PK Tolerability in Children and Adolescents
Biomarkers to Enhance Early Schizophrenia Treatment
Recall (Class II): ARIPIPRAZOLE
Drug Safety Update: Aripiprazole (Abilify and generic brands): risk of pathological gambling
Approval: Aripiprazole Accord (EMA)
Approval: Aripiprazole Sandoz (EMA)
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Pharmacology & targets
Known molecular targets and mechanisms supported by curated pharmacology databases.
Regulatory timeline
The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.
Indication: Aripiprazole Accord is indicated for the treatment of schizophrenia in adults and in adolescents aged 15 years and older. Aripiprazole Accord is indicated for the treatment of… Show full indicationShow less
Aripiprazole Accord is indicated for the treatment of schizophrenia in adults and in adolescents aged 15 years and older. Aripiprazole Accord is indicated for the treatment of moderate to severe manic episodes in Bipolar I Disorder and for the prevention of a new manic episode in adults who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment. Aripiprazole Accord is indicated for the treatment up to 12 weeks of moderate to severe manic episodes in Bipolar I Disorder in adolescents aged 13 years and older.
Indication: Aripiprazole Sandoz is indicated for the treatment of schizophrenia in adults and in adolescents aged 15 years and older. Aripiprazole Sandoz is indicated for the treatment of… Show full indicationShow less
Aripiprazole Sandoz is indicated for the treatment of schizophrenia in adults and in adolescents aged 15 years and older. Aripiprazole Sandoz is indicated for the treatment of moderate to severe manic episodes in Bipolar I Disorder and for the prevention of a new manic episode in adults who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment. Aripiprazole Sandoz is indicated for the treatment up to 12 weeks of moderate to severe manic episodes in Bipolar I Disorder in adolescents aged 13 years and older.
Indication: Aripiprazole Mylan Pharma is indicated for the treatment of schizophrenia in adults and in adolescents aged 15 years and older. Aripiprazole Mylan Pharma is indicated for the… Show full indicationShow less
Aripiprazole Mylan Pharma is indicated for the treatment of schizophrenia in adults and in adolescents aged 15 years and older. Aripiprazole Mylan Pharma is indicated for the treatment of moderate to severe manic episodes in Bipolar I Disorder and for the prevention of a new manic episode in adults who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment. Aripiprazole Mylan Pharma is indicated for the treatment up to 12 weeks of moderate to severe manic episodes in Bipolar I Disorder in adolescents aged 13 years and older.
Data from the U.S. Food and Drug Administration (U.S. Food and Drug Administration), public domain (CC0).
Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.
Contains public sector information from the Medicines and Healthcare products Regulatory Agency (MHRA) licensed under the Open Government Licence (OGL v3).
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Late-stage studies
Phase III+ trials still open or recently active — where late-stage evidence is being generated.
Biomarkers to Enhance Early Schizophrenia Treatment
Cerebellar-cortical Circuitry and Prediction of Treatment Response in Early Psychosis
Recent completions
Trials that read out recently, adding to the completed evidence base.
The Impact of Aripiprazole Long-acting on Myelin and Cognition in the Onset of Schizophrenia
Aripiprazole for Bipolar Disorder and Alcohol Use Disorder
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Major research themes4
Journals, researchers & institutions
- The Journal of clinical psychiatry2
- Addiction (Abingdon, England)1
- Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists1
- Journal of child and adolescent psychopharmacology1
- Journal of clinical psychopharmacology1
- Adegbite C1
- Barnett M1
- Calabrese JR1
- Calarge C1
- Clark C1
- Coffin PO1
- Colfax GN1
- Cutler AJ1
- Clinical Development1
- Stanford University Medical Center1
- University Hospitals1
- University of Iowa1
- University of Pittsburgh School of Pharmacy1
- UPMC Western Psychiatric Hospital1
Related drugs
Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).
Acts on the same molecular target as Aripiprazole, with an overlapping disease area.
- RxNorm (U.S. National Library of Medicine) — drug identity
- ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
- Europe PMC — research literature
- ClinicalTrials.gov — clinical trials
- Regulatory event sources are credited in the Regulatory Timeline above.